Search - tctmd.com

Displaying 21 - 31 of 31

Sort: Relevancy | Date

Presentation TCT 2013

Vulnerable Plaque Diagnosis by MSCT (with Case Vignettes)

Presenter: James Min

October 30, 2013

Presentation TCT 2013

Annulus Sizing Using MSCT Is Now the Gold Standard and Helps to Reduce Paravalvular Regurgitation After TAVR

Presenter: Jonathon Leipsic

October 28, 2013

News Industry News

Elixir Medical Corporation to Announce 6-month Results of the DESolve Fully Bioresorbable Coronary Scaffold System Pivotal Trial at Late Breaking Trial Session of EuroPCR

May 01, 2013

Presentation TCT 2013

Rotational angiography with 3D reconstruction following motion field estimation for evaluation of geometry of the implanted Medtronic Corevalve frame: comparison with MSCT

Presenter: Carl Schultz, Peter De Jaegere, Nicolas Van Mieghem

January 31, 2013

News Industry News

Elixir Medical Announces Enrollment Completion of the DESolve Nx Pivotal Trial for Fully Bioresorbable Coronary Scaffold System

October 25, 2012

Presentation TCT 2012

3-D Annulus Sizing (using MSCT or 3-D Echo) Is Now the Gold Standard and Helps to Reduce Paravalvular Regurgitation After TAVR

Presenter: Hasan Jilaihawi

October 22, 2012

Presentation TVT 2012

Snapshot I. Annulus Sizing: 3-D MSCT Is Now the "Gold Standard"

Presenter: Jonathon Leipsic

June 03, 2012

Presentation TVT 2012

MSCT Should Be the 'Gold Standard' for Valve Sizing Strategies

Presenter: Jonathon Leipsic

June 03, 2012

Presentation CTO 2012

Utility of MSCT in Planning CTO Revascularization

Presenter: Satoru Sumitsuji

February 23, 2012

News Industry News

Elixir Medical Announces DESolve Nx International Pivotal Trial Initiation for Fully Bioresorbable Coronary Scaffold System

November 10, 2011

News Industry News

Clinical trial that compared transapical transcatheter aortic valve replacement to surgical aortic valve replacement

November 09, 2011

Advertisement

Vulnerable Plaque Diagnosis by MSCT (with Case Vignettes)

Annulus Sizing Using MSCT Is Now the Gold Standard and Helps to Reduce Paravalvular Regurgitation After TAVR

Elixir Medical Corporation to Announce 6-month Results of the DESolve Fully Bioresorbable Coronary Scaffold System Pivotal Trial at Late Breaking Trial Session of EuroPCR

Rotational angiography with 3D reconstruction following motion field estimation for evaluation of geometry of the implanted Medtronic Corevalve frame: comparison with MSCT

Elixir Medical Announces Enrollment Completion of the DESolve Nx Pivotal Trial for Fully Bioresorbable Coronary Scaffold System

3-D Annulus Sizing (using MSCT or 3-D Echo) Is Now the Gold Standard and Helps to Reduce Paravalvular Regurgitation After TAVR

Snapshot I. Annulus Sizing: 3-D MSCT Is Now the "Gold Standard"

MSCT Should Be the 'Gold Standard' for Valve Sizing Strategies

Utility of MSCT in Planning CTO Revascularization

Elixir Medical Announces DESolve Nx International Pivotal Trial Initiation for Fully Bioresorbable Coronary Scaffold System

Clinical trial that compared transapical transcatheter aortic valve replacement to surgical aortic valve replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content